



(51) Clasificación Internacional de Patentes ⁶ : A61K 38/21	A1	(11) Número de publicación internacional: WO 99/58143 (43) Fecha de publicación internacional: 18 de Noviembre de 1999 (18.11.99)
(21) Solicitud internacional: PCT/ES99/0134 (22) Fecha de la presentación internacional: 13 de Mayo de 1999 (13.05.99) (30) Datos relativos a la prioridad: P 9801003 13 de Mayo de 1998 (13.05.98) ES (71) Solicitante (para todos los Estados designados salvo US): INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A. [ES/ES]; Avenida Pio XII, 53, E-31008 Pamplona (ES). (72) Inventores; e (75) Inventores/solicitantes (sólo US): PRIETO VALTUEÑA, Jesús [ES/ES]; Tudela, 22 - 4º, E-31002 Pamplona (ES). CIVEIRA MURILLO, Mª Pilar [ES/ES]; Irunlarrea, 35 - 1º, E-31008 Pamplona (ES). LARREA LEOZ, Esther [ES/ES]; Avenida Sancho el Fuerte, 34 - 3º C, E-31008 Pamplona (ES). (74) Mandatario: DE ELZABURU, Alberto; Miguel Angel, 21, E-28010 Madrid (ES).	(81) Estados designados: AE, AT, AU, BE, BF, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW. Patente ARIPO (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW). Patente euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). Patente europea (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Patente OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Publicada Con informe de búsqueda internacional.	
(54) Title: UTILIZATION OF INTERFERON ALPHA 5 IN THE TREATMENT OF VIRAL HEPATOPATHIES		
(54) Título: USO DEL INTERFERON ALFA 5 EN EL TRATAMIENTO DE LAS HEPATOPATIAS VIRALES		
(57) Abstract <p>The invention relates to the use of the interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the sub-type alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers and others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.</p> <div style="display: flex; justify-content: space-around;"> <div data-bbox="352 750 518 1039"> <p>A</p> <p>C HCV-RNA(+)</p> </div> <div data-bbox="663 750 828 1039"> <p>B</p> <p>C HCV-RNA(+)</p> </div> </div>		